Peptide Compounding Status (October 2026)

Primary entity: Peptide compounding status (U.S.) · Covers: BPC-157, TB-500, MOTS-c, Semax, Epitalon, KPV and other peptides · Related: Research peptides guide · BPC-157 · TB-500 · Disclaimers

On Oct 28, 2026, HHS announced an interim policy that it does not intend to take enforcement action against licensed U.S. pharmacies (and licensed physicians) that compound six peptides — BPC-157, TB-500, MOTS-c, Semax, Epitalon and KPV — for individual patients with a prescription, if a list of conditions is met. That is a temporary enforcement stance, not an FDA approval; it does not cover any other peptide, research-use-only vials, or blends.

Who this page is for — and not for

For: readers trying to make sense of headlines about "peptides being legal again," writers, and anyone separating compounded, research-use-only, and approved products.

Not for: finding a pharmacy or clinic, deciding whether to use a peptide, or dosing. We don't recommend providers, sell anything, or give protocols. Whether any of this is appropriate for you is a question for a licensed prescriber.

Questions this page answers

1. What did HHS actually announce?
2. What are 503A, 503B, bulks lists, and "Category 2"?
3. How did we get here? (timeline)
4. Which peptides are covered, and how?
5. What are the conditions?
6. What this does NOT mean
7. Where do other peptides stand?
8. What about semaglutide and tirzepatide?
9. Compounded vs research-use-only vs approved
10. What's still unverified or unsettled?

What did HHS actually announce?

HHS published an "interim enforcement-discretion policy" for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act using certain peptide bulk drug substances. In plain terms: while the formal rulemaking process on the 503A bulks list plays out, HHS says it "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility, or licensed physician that compounds a qualifying product under the stated conditions. HHS reserves the right to revisit the policy if a safety signal or quality problem appears.

Enforcement discretion is a decision not to prosecute under stated conditions. It does not change the law, approve a drug, or declare a product safe or effective.

What are 503A, 503B, bulks lists, and "Category 2"?

How did we get here?

Press reports (including from the Associated Press) say FDA scientific staff had little input and opposed the changes. That's attributed to unnamed sources; FDA has not confirmed it, and we treat it as reported, not established.

Which peptides are covered, and how?

Per the policy's appendix (our reading of the HHS document — confirm on the source):

Coverage is specific: a different salt form, route, or a combination product falls outside it. TB-500 here is the synthetic fragment, not full-length thymosin beta-4.

What are the conditions?

In summary (not a substitute for the HHS text):

1. The peptide, form and route match the policy's appendices.
2. The bulk substance comes from an FDA-registered establishment, with a certificate of analysis meeting listed testing criteria (identity, assay, impurities, endotoxin and similar).
3. The original manufacturer is registered and meets current good manufacturing practice, and the COA identifies the facility.
4. The pharmacy reports products, serious adverse events and quality problems to FDA's MedWatch and states.
5. The label says: "This is a compounded drug product. Not for resale."
6. Single active ingredient — so, on one law firm's reading, no BPC-157 + TB-500 blends.
7. Oral forms need documentation of adequate oral bioavailability.
8. The only co-packaged device allowed is an FDA-cleared syringe.
9. A valid patient-specific prescription, no insanitary conditions, and all other 503A requirements.

What this does NOT mean

• It does not mean these peptides are FDA-approved. Compounded drugs are not FDA-approved; FDA doesn't review them for safety, effectiveness or quality before they're sold.
• It does not mean they're proven safe or effective. The policy is about enforcement priorities. For most of these peptides, human trial evidence is limited or absent (see each profile).
• It does not legalize research-use-only vials. RUO sales and dietary-supplement channels are outside the policy, and FDA sent warning letters to RUO sellers in August 2026.
• It does not remove the prescription requirement. Nothing here lets someone buy these over the counter or compound for themselves.
• It does not cover 503B outsourcing facilities.
• It does not cover other peptides — see below.
• It is not permanent. It's interim, revocable, and sits ahead of formal rulemaking that could take a long time (one law firm estimates 12–24 months — an estimate, not an FDA commitment).
• State rules still apply and may be stricter; we haven't surveyed them.

Where do other peptides stand?

"Removed from Category 2" sounds like a green light. It isn't: in most cases it happened because the person who nominated the substance withdrew the nomination, and HHS says that didn't change the legal status under 503A.

What about semaglutide and tirzepatide?

The Oct 28 policy doesn't address GLP-1 drugs. Both are FDA-approved (Ozempic, Wegovy, Rybelsus; Mounjaro, Zepbound). FDA declared the tirzepatide shortage resolved in Oct–Dec 2024 and the semaglutide shortage resolved on Feb 21, 2025, and courts denied the compounders' bids to block those decisions in 2025. Under 503A, a compounder may not regularly make a product that is "essentially a copy" of an approved drug (same ingredient, similar strength, same route) unless a prescriber documents a significant clinical difference; 503B facilities can't use these substances from a bulks list because neither is on it. FDA's April 2026 update restates this. See the semaglutide and tirzepatide profiles.

Compounded vs research-use-only vs approved

What's still unverified or unsettled?

• Final Federal Register text (scheduled Oct 30) — we read the HHS-posted policy; wording may differ, and the comment period may bring changes.
• Advisory committee vote tallies — from secondary reporting; official minutes not reviewed.
• Non-injectable GHK-Cu category status — single secondary source.
• December 2024 advisory outcomes for CJC-1295, AOD-9604 and thymosin alpha-1.
• Press reports of internal FDA disagreement — attributed to unnamed sources.
• Litigation: we found no lawsuit challenging the new policy as of Oct 29; that could change.
• Next steps: a second advisory meeting for other peptides was reported as expected by early 2027, with no date set.

Frequently asked questions

Sources

1. HHS. Enforcement discretion policy — 503A peptide bulk drug substances (policy and Appendix B), PDF. Read Oct 29, 2026.
2. Federal Register. Public inspection document 2026-22192 — scheduled for publication Oct 30, 2026.
3. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page).
4. FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated Apr 1, 2026).
5. FDA. Warning letter: NuScience Peptides LLC, Aug 24, 2026.
6. FDA. PCAC meeting briefing materials (June–July 2026).
7. BakerHostetler. HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (Oct 28, 2026) — secondary.
8. Frier Levitt. HHS peptide compounding enforcement discretion policy (Oct 28, 2026) — secondary.
9. NPR. Peptides compounding enforcement (Oct 28, 2026) — secondary.
10. Associated Press. Peptides, FDA and compounding — secondary.
11. Holland & Knight. Peptides at a crossroads (Oct 2026) — secondary.
12. Reed Smith via Lexology. Category 2 nomination withdrawals (Oct 1, 2024) — secondary. Last checked: Oct 29, 2026.